Company / Cash & Equivalents
Cue Biopharma, Inc. Cash & Equivalents History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$27.1M
FY2025
5-year range
$22.5M / $64.4M
FY2021-FY2025
Trend
+20.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents returned to growth in FY2025 after 4 years of decline, reaching $27M.
Based on SEC 10-K filings.
$27M in FY2025 with a 5-year CAGR of -18.4%.
Declined from $49M to $27M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -19.3%
- 5-Year CAGR
- -18.4%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -18.4%, indicating a declining trend.
- In FY2025, cash & equivalents increased 20.8% year-over-year.
- Peak cash & equivalents was recorded in FY2020.
- Lowest cash & equivalents in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score -7.60 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $27.1M | +20.8% |
| FY2024 | $22.5M | -53.7% |
| FY2023 | $48.5M | -6.0% |
| FY2022 | $51.6M | -19.8% |
| FY2021 | $64.4M | -14.0% |
| FY2020 | $74.9M | +69.0% |
| FY2019 | $44.3M | - |
| FY2018 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026